369654-36-4

Upstream product

• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 370594-54-0 methyl 4-{[{[t-butyloxy]carbonyl}(2-pyridinylmethyl)amino]methyl}benzoate 

Downstream Products

• 369656-61-1 N-[(1S)-1-(1-naphthyl)ethyl]-4-(methoxycarbonyl)-2-(S)-[4-[N-Boc-N-(pyridin-2-ylmethyl)aminomethyl]benzoylamino]butyrylamide 
• 369656-37-1 Nα-4-(N-Boc-N-2-picolylaminomethyl)benzoyl-NG-nitro-L-arginine (1'S)-1'-(1-naphthyl) ethylamide 
• 370594-71-1 Nα-(4-(N-Boc-N-2-picolylaminomethyl)benzoyl)-NG-Pmc-L-arginine 1-naphthalenemethyl amide 
• 369656-34-8 Nα-(4-(N-Boc-N-2-picolylaminomethyl)benzoyl)-Nδ-Boc-L-ornithine (1'S)-1'-(1-naphthyl) ethylamide 
• 369656-18-8 Nα-(4-(N-Boc-N-(2-picolyl)aminomethyl)benzoyl)-Nδ-Boc-L-ornithinemethylester 
• 370594-88-0 Nα-4-(N-Boc-N-2-picolylaminomethylbenzoyl)-L-gultamate 1-naphthalenemethylamide γ-methylester 
• 369654-38-6 Nα-4-(N-Boc-N-2-picolylaminomethyl)benzoyl-Nδ-Cbz-L-ornithine 1-naphthalenemethylamide 
• 369656-69-9 [(1S)-1-(1-naphthyl)ethyl]-5-amino-(S)-2-[4-[N-Boc-N-(pyridin-2-ylmethyl)aminomethyl]benzoyl]aminopentanoylamide 

Relevant academic research and scientific papers

Probing the Molecular Interactions between CXC Chemokine Receptor 4 (CXCR4) and an Arginine-Based Tripeptidomimetic Antagonist (KRH-1636)

We here report an experimentally verified binding mode for the known tripeptidomimetic CXCR4 antagonist KRH-1636 (1). A limited SAR study based on the three functionalities of 1 was first conducted, followed by site-directed mutagenesis studies. The recep

CXCR4-ANTAGONISTIC DRUGS COMPRISING NITROGEN-CONTAINING COMPOUND

To provide novel nitrogen-containing compounds having antagonism to CXCR4 and remedies for disease, such as rheumatism, cancer metastasis, etc., based on the CXCR4 antagonism. Nitrogen-containing compounds represented by the following general formula and

NOVEL NITROGENOUS COMPOUND AND USE THEREOF

A novel nitrogen-containing compound effective against diseases such as HIV viral infectious diseases, rheumatism, and cancerous metastasis. It is a nitrogen-containing compound represented by the following general formula (1). In the formula, A typically represents a group represented by the formula (2) (A1 is hydrogen or an optionally substituted, mono- or polycyclic, heteroaromatic or aromatic ring; G1 is a single bond or a hydrocarbon group represented by the following formula (3) wherein R1, R2, and R3 may be optionally substituted hydrocarbon groups); W is an optionally substituted hydrocarbon group or heterocyclic ring; x is -C(=O)NH-; y is -C(=O)-; and D1 is hydrogen atom, alkyl having a polycyclic aromatic ring, di (substituted alkyl)amine, or alicyclic amine.

NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME

The present invention provides novel compounds having antiviral activities and antiviral drugs containing the compounds as the active ingredient. The compounds are shown by the following general formula (1), wherein typically A1 and A2 are each guanidine or a group of the general fomula (ia) ; A3 is a mono- or poly-cyclic heteroaromatic ring contining 1 or 2 heteroatoms ; B1 is a single bond or alkylene group; R1 is hydrogen or alkyl group; W is an alkylene having 2-3 carbons, a cycloalkylene having 5-10 carbons, aromatic ring having 6-10 carbons, or a heteroaromatic ring having 5-10 carbons; y is C(=O)-; x is -C(=O)-NH-; n1 is an integer of 1-2; n2 is an integer of 2-3; D is a substituent selected from among various groups.